GLPwatch

A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity

NCT04102189 · Completed

Last updated 2026-05-28

This study is testing how well the medication semaglutide works to help adolescents who are overweight or have obesity.

Status Completed The study has finished.
Phase Phase 3 Confirms effectiveness in a large group before approval.
Type Interventional (clinical trial)
Design Randomized, double-blind treatment study
Participants 201 people
Who can join Ages 12–17 · all sexes
Timeline Started 2019-10 · est. completion 2022-03
Where 51 sites · Austria, Belgium, Croatia, Ireland, Mexico, Russia, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT04102189 ↗

Description as written by the study sponsor.

This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy" medicine. The teenagers in the study and their parents will also have talks with study staff about healthy food choices, how to be more physically active and what they can do to help the teenagers lose weight. The teenagers will either get semaglutide or "dummy" medicine - which treatment is decided by chance. The teenagers will take 1 injection every week, on the same day of the week for about 15 months. The study medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm. The teenagers will have 17 clinic visits, will have blood samples taken and will have to complete questionnaires and keep a diary. All this will be explained before study start.

Treatments tested

Main thing measuredChange in Body Mass Index (BMI) (Percentage [%])
SponsorNovo Nordisk A/S
Conditions studiedOverweight, Obesity
GLP-1 drugs semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT04102189 ↗